A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 And Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04792489

Study #:
STUDY00147110

Start Date:
Nov 15, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04792489

View Complete Trial Details & Eligibility at ClinicalTrials.gov